Limits...
International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer.

Tomita N, Oze I, Shimizu H, Yoshida M, Kimura K, Takehana K, Shimizu A, Makita C, Tachibana H, Kodaira T, Soga N, Ogura Y, Hayashi N - Nagoya J Med Sci (2015)

Bottom Line: Patients were evaluated in three groups according to baseline IPSS as defined by the American Urological Association classification, where IPSSs of 0 to 7, 8 to 19, and 20 to 35 represent mild (n = 124), moderate (n = 70), and severe (n = 22) symptom groups, respectively.Among factors of patient and treatment characteristics, age, IPSS classification, pretreatment GU medications, and positive biopsy rates were associated with the IPSS difference between baseline and 24 months (P = 0.023, < 0.001, 0.044, and 0.028, respectively).Age, baseline IPSS, GU medications, and tumor burden in the prostate can have an effect on the IPSS changes.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

ABSTRACT
The purposes of this study on prostate cancer are to demonstrate the time course of International Prostate Symptom Score (IPSS) after intensity-modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) and to examine the factor associated with the IPSS change. This study included 216 patients treated with IMRT between 2006 and 2010. Patients were evaluated in three groups according to baseline IPSS as defined by the American Urological Association classification, where IPSSs of 0 to 7, 8 to 19, and 20 to 35 represent mild (n = 124), moderate (n = 70), and severe (n = 22) symptom groups, respectively. The average IPSSs ± standard deviation at baseline vs. those at 24 months after IMRT were 3.5 ± 2.1 vs. 5.1 ± 3.6 in the mild group (P < 0.001), 12.6 ± 3.4 vs. 10.0 ± 6.0 in the moderate group (P = 0.0015), and 23.8 ± 2.9 vs. 14.4 ± 9.1 in the severe group (P < 0.001). Among factors of patient and treatment characteristics, age, IPSS classification, pretreatment GU medications, and positive biopsy rates were associated with the IPSS difference between baseline and 24 months (P = 0.023, < 0.001, 0.044, and 0.028, respectively). In conclusion, patients with moderate to severe urinary symptoms can exhibit improvement in urinary function after IMRT, whereas patients with mild symptoms may have slightly worsened functions. Age, baseline IPSS, GU medications, and tumor burden in the prostate can have an effect on the IPSS changes.

No MeSH data available.


Related in: MedlinePlus

IPSS trends of three groups after IMRT combined with ADT according to the AUA classification.Bars and lines represent mean IPSSs and standard deviations at each time.* means statistically significant (P < 0.01) compared with those at baseline in each group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664595&req=5

fig1: IPSS trends of three groups after IMRT combined with ADT according to the AUA classification.Bars and lines represent mean IPSSs and standard deviations at each time.* means statistically significant (P < 0.01) compared with those at baseline in each group.

Mentions: IPSS significantly changed over time in all patients (P < 0.001). The average IPSS was highest at three months after IMRT and lowest at 24 months after IMRT. Figure 1 the shows IPSS courses in the three groups according to the AUA classification. The average IPSS significantly changed over time in all three groups (all P < 0.001). The average IPSS was lowest at baseline (3.5 ± 2.1), highest at three months after IMRT (8.1 ± 5.5), and second lowest at 24 months after IMRT (5.1 ± 3.6) in the mild group. The average IPSS at 24 months after IMRT was significantly higher than that at baseline in the mild group (5.1 ± 3.6 vs. 3.5 ± 2.1, P < 0.001). In the moderate group, the highest average IPSS was at three months after IMRT (12.9 ± 6.5) and the lowest was at 24 months after IMRT (10.0 ± 6.0). The average IPSS at 24 months after IMRT was significantly lower than that at baseline in the moderate group (10.0 ± 6.0 vs. 12.6 ± 3.4, P = 0.0015). In the severe group, the average IPSS was highest at baseline (23.8 ± 2.9) and lowest at 6 months after IMRT (13.5 ± 7.1). The average IPSS at 24 months after IMRT was significantly lower than that at baseline in the severe group (14.4 ± 9.1 vs. 23.8 ± 2.9, P < 0.001).


International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer.

Tomita N, Oze I, Shimizu H, Yoshida M, Kimura K, Takehana K, Shimizu A, Makita C, Tachibana H, Kodaira T, Soga N, Ogura Y, Hayashi N - Nagoya J Med Sci (2015)

IPSS trends of three groups after IMRT combined with ADT according to the AUA classification.Bars and lines represent mean IPSSs and standard deviations at each time.* means statistically significant (P < 0.01) compared with those at baseline in each group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664595&req=5

fig1: IPSS trends of three groups after IMRT combined with ADT according to the AUA classification.Bars and lines represent mean IPSSs and standard deviations at each time.* means statistically significant (P < 0.01) compared with those at baseline in each group.
Mentions: IPSS significantly changed over time in all patients (P < 0.001). The average IPSS was highest at three months after IMRT and lowest at 24 months after IMRT. Figure 1 the shows IPSS courses in the three groups according to the AUA classification. The average IPSS significantly changed over time in all three groups (all P < 0.001). The average IPSS was lowest at baseline (3.5 ± 2.1), highest at three months after IMRT (8.1 ± 5.5), and second lowest at 24 months after IMRT (5.1 ± 3.6) in the mild group. The average IPSS at 24 months after IMRT was significantly higher than that at baseline in the mild group (5.1 ± 3.6 vs. 3.5 ± 2.1, P < 0.001). In the moderate group, the highest average IPSS was at three months after IMRT (12.9 ± 6.5) and the lowest was at 24 months after IMRT (10.0 ± 6.0). The average IPSS at 24 months after IMRT was significantly lower than that at baseline in the moderate group (10.0 ± 6.0 vs. 12.6 ± 3.4, P = 0.0015). In the severe group, the average IPSS was highest at baseline (23.8 ± 2.9) and lowest at 6 months after IMRT (13.5 ± 7.1). The average IPSS at 24 months after IMRT was significantly lower than that at baseline in the severe group (14.4 ± 9.1 vs. 23.8 ± 2.9, P < 0.001).

Bottom Line: Patients were evaluated in three groups according to baseline IPSS as defined by the American Urological Association classification, where IPSSs of 0 to 7, 8 to 19, and 20 to 35 represent mild (n = 124), moderate (n = 70), and severe (n = 22) symptom groups, respectively.Among factors of patient and treatment characteristics, age, IPSS classification, pretreatment GU medications, and positive biopsy rates were associated with the IPSS difference between baseline and 24 months (P = 0.023, < 0.001, 0.044, and 0.028, respectively).Age, baseline IPSS, GU medications, and tumor burden in the prostate can have an effect on the IPSS changes.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

ABSTRACT
The purposes of this study on prostate cancer are to demonstrate the time course of International Prostate Symptom Score (IPSS) after intensity-modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) and to examine the factor associated with the IPSS change. This study included 216 patients treated with IMRT between 2006 and 2010. Patients were evaluated in three groups according to baseline IPSS as defined by the American Urological Association classification, where IPSSs of 0 to 7, 8 to 19, and 20 to 35 represent mild (n = 124), moderate (n = 70), and severe (n = 22) symptom groups, respectively. The average IPSSs ± standard deviation at baseline vs. those at 24 months after IMRT were 3.5 ± 2.1 vs. 5.1 ± 3.6 in the mild group (P < 0.001), 12.6 ± 3.4 vs. 10.0 ± 6.0 in the moderate group (P = 0.0015), and 23.8 ± 2.9 vs. 14.4 ± 9.1 in the severe group (P < 0.001). Among factors of patient and treatment characteristics, age, IPSS classification, pretreatment GU medications, and positive biopsy rates were associated with the IPSS difference between baseline and 24 months (P = 0.023, < 0.001, 0.044, and 0.028, respectively). In conclusion, patients with moderate to severe urinary symptoms can exhibit improvement in urinary function after IMRT, whereas patients with mild symptoms may have slightly worsened functions. Age, baseline IPSS, GU medications, and tumor burden in the prostate can have an effect on the IPSS changes.

No MeSH data available.


Related in: MedlinePlus